Max Philip retweetet
Congratulations to Dr. Mona Al‑Gizawiy of the Medical College of Wisconsin on securing a new NIH R01 award—and to announce our role as a sub‑award recipient on this important project. This five‑year, $3M grant will accelerate the understanding of gallium maltolate (GaM), a promising oral therapy targeting some of the most aggressive pediatric brain cancers.
Under Dr. Al‑Gizawiy’s leadership, the pre-clinical project will advance the combination of GaM with radiation therapy, building on early evidence that GaM can enhance treatment effectiveness. IB will support this work with our FDA‑cleared quantitative MR imaging platform—including our advanced Fractional Tumor Burden (FTB) maps—which delivers standardized, highly sensitive measures of tumor response. This capability is essential for evaluating emerging therapies and represents a key differentiator in the neuro‑oncology imaging market.
“IB’s quantitative imaging gives us an early and reliable window into how tumors respond to treatment—something conventional scans simply can’t match,” said Dr. Al‑Gizawiy.
IB packages pre-clinical imaging workflows to create a unified imaging ecosystem that strengthens our position across research and clinical markets. This initiative supports long‑term growth by expanding IB’s footprint in translational research and multi‑site trials.
#PediatricBrainCancer #ChildhoodCancerResearch #PediatricOncology #BrainTumorResearch #DIPG #Glioblastoma #ATRT #HighGradeGlioma #ftbmaps
English
